India May Take WTO Action after EMA Drug Suspension

April 16, 2015
Pharmaceutical Technology Editors

India may go to the World Trade Organization if the EU does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences.

Reuters reports

that India may go to the World Trade Organization (WTO) if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences.    EMA's 

suspension

 became effective in January, a month after France, Germany, Belgium, and Luxembourg suspended the sale of 25 generic drugs that were approved based on trials conducted by GVK Biosciences.   Drugs suspended by EMA include those made by US firms Mylan Inc and Abbott Laboratories, as well as large Indian companies such as Lupin and Dr Reddy's Laboratories.   After an appeal by the company, the Indian government set up a panel of experts last year to investigate the matter and found no manipulation, GVK Biosciences CEO Manni Kantipudi told Reuters.   If the suspension is not reconsidered New Delhi could take action at the WTO.